- Samsung BioLogics announced that it is mass-producing a COVID-19 antibody treatment developed by Eli Lilly (NYSE:LLY), as the U.S. began distributing the drug last week after emergency-use nod for bamlanivimab earlier this month.
- The FDA said the drug can be used for people aged 65 and over who have recently been diagnosed with mild-to-moderate COVID-19 and those aged 12 and over who have underlying health conditions putting them at risk of serious illness.
- Lilly aims to manufacture up to 1M doses by year end, and expects supply to increase substantially from the first quarter of 2021 as additional manufacturing resources come online.
- Samsung said it has a long-term manufacturing contract with Lilly, with details not disclosed.
- https://seekingalpha.com/news/3637101-samsung-biologics-mass-producing-eli-lillys-covidminus-19-treatment
Tuesday, November 17, 2020
Samsung BioLogics mass producing Eli Lilly's COVID-19 treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.